β-Adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats

Hypertension

Volumn 24, Issue 6, 1994, Pages 653-662

  Böhm, Michael ^a   Moll, Marianne ^a   Schmid, Bernhard ^a   Paul, Martin ^b   Ganten, Detlev ^b   Castellano, Maurizio ^c   Erdmann, Erland ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Max Delbruck Zentrum F Molec M ^*  (Germany)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

adenyl cyclase; heart failure; heart hypertrophy; hypertension, genetic; rats, transgenic; receptors, adrenergic, beta; renin angiotensin system

Indexed keywords

ADENYLATE CYCLASE; ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROPEPTIDE Y; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; GENETIC ANALYSIS; HEART VENTRICLE HYPERTROPHY; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSGENIC MOUSE;

EID: 0028171354     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.24.6.653     Document Type: Article

References (59)

1. Grossman W, Jones D, McLaurin KP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;58:56-64.
2. Spann JF Jr, Buccino RA, Sonnenblick EH, Braunwald E. Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circ Res. 1967;21:341-354.
3. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure: the Framingham Study. N Engl J Med. 1972;287:781-787.
4. Dzau V, Colucci W, Hollenberg N, Williams G. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63:645-656.
5. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation. 1988;77:721-730.
6. Swedberg K, Viquerat C, Rouleau J-L, Roizen M, Atherton B, Parmley WW, Chatterjee K. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol. 1984;54:783-789.
7. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkamn K, Murray J, et al. Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:1024-1039.
8. Bristow MR, Ginsburg R, Minobe W, Cibiccioti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
9. Brodde O-E. β1- and β2-Adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203-242.
10. Böhm M, Beuckelmann D, Brown L, Feiler G, Lorenz B, Näbauer M, Kemkes B, Erdmann E. Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur Heart J. 1988;9:844-852.
11. Böhm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E. Increase of Giα in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 1990;82:1249-1265.
12. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 1988;82:189-197.
13. Neumann J, Schmitz W, von Meyerinck L, Scholz H, Döring V, Kalmar P. Increase in myocardial Gi-proteins in heart failure. Lancet. 1988;2:936-937.
14. Ganten D, Lindpaintner K, Ganten U, Peters J, Zimmermann F, Bader M, Mullins J. Transgenic rats: new animal models in hypertension research. Hypertension. 1991;17:843-855.
15. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 1990;344:541-544.
16. Böhm M, Pieske B, Schnabel P, Schwinger RHG, Kemkes B, Klövekorn W-P, Erdmann E. Reduced effects of dopexaraine on force of contraction in the failing human heart despite preserved β2-adrenoceptor subpopulation. J Cardiovasc Pharmacol. 1989;14:549-559.
17. Böhm M, Gierschik P, Knorr A, Larisch K, Weismann K, Erdmann E. Desensitization of adenylate cyclase and increase of Giα in cardiac hypertrophy due to acquired hypertension. Hypertension. 1992;20:103-112.
18. 125I-labeled C-terminal decapeptide of retinal transducin. Biochem J. 1991;277:223-229.
19. Goldsmith P, Gierschik P, Milligan G, Unson CG, Vinitsky R, Malech HL, Spiegel AM. Antibodies directed against synthetic peptides distinguish between GTP-binding proteins in neutrophils and brain. J Biol Chem. 1987;262:14683-14688.
20. Sternweis PC, Northup JK, Smigel MD, Gilman AG. The regulatory component of adenylate cyclase. J Biol Chem. 1981;256:11517-11526.
21. Beschi M, Castellano M, Agabiti-Rosei C, Rizzoni D, Rossini P, Muliesan G. Assessment of semi-automated catecholamine assay by HPLC: choice of reverse phase C18 or cation-exchange columns. Chromatographia. 1987;24:455-459.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
23. Lämmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
24. Dixon TF, Purdom M. Serum 5′nucleotidase. J Clin Pathol. 1954;7:341-351.
25. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulatory research. Circ Res. 1980;47:1-9.
26. Seamon KB, Daly JW. Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1989;20:1-150.
27. Limbird LE, Hickey AR, Lefkowitz RJ. Unique uncoupling of the frog erythrocyte adenylate cyclase system by manganese: loss of hormone and guanine nucleotide-sensitive enzyme activities without loss of nucleotide-sensitive, high affinity agonist binding. J Biol Chem. 1979;254:2677-2683.
28. Cech SY, Broaddus WC, Maguire ME. Adenylate cyclase: the role of magnesium and other divalent cations. Mol Cell Biochem. 1980;33:67-92.
29. Jeunemaitre X, Soubrier F, Kotelevtsev V, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
30. Kurtz TW, St. Lezin EM. Gene mapping in experimental hypertension. J Am Soc Nephrol. 1992;3:28-34.
31. Kurtz TW, Montano M, Chan L, Kabra P. Molecular evidence of genetic heterogeneity in Wistar-Kyoto rats: implications for research with the spontaneously hypertensive rat. Hypertension. 1989;13:188-192.
32. Zimmermann BG. Adrenergic facilitation by angiotensin: does it serve a physiological function? Clin Sci (Colch). 1981;60:343-348.
33. Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol. 1977;77:1-24.
34. Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol. 1987;49:413-435.
35. Reit E. Actions of angiotensin on the adrenal medulla and autonomic ganglia. Fed Proc. 1972;31:1338-1343.
36. Reiter M. Calcium mobilization and cardiac inotropic mechanisms. Pharmacol Rev. 1988;40:189-217.
37. 1-receptor downregulation in heart failure. Circ Res. 1986;59:297-309.
38. 2-receptors of human heart: differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol. 1985;331:60-70.
39. 2-adrenoceptors in rat models of acquired hypertension. J Cardiovasc Pharmacol. 1988;13:421-431.
40. Böhm M, Gierschik P, Knorr A. Schmidt U, Weismann K, Erdmann E. Myocardial adenylyl cyclase, β-adrenoceptors, and G-proteins in salt-sensitive hypertension. Hypertension. 1993;22:715-727.
41. Limas C, Limas CJ. Cardiac β-adrenergic receptors in salt-dependent genetic hypertension. Hypertension. 1985;7:760-766.
42. Anand-Srivastava MB. Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Biochem J. 1992;288:79-85.
43. Böhm M, Gierschik P, Knorr A, Larisch K, Weismann K, Erdmann E. Role of altered G-protein expression in the regulation of myocardial adenylate cyclase activity and force of contraction in spontaneous hypertensive cardiomyopathy in rats. J Hypertens. 1992;10:1115-1128.
44. Peters J, Munter K, Bader M, Hackenthal E, Mullins JJ, Ganten D. Increased adrenal renin in transgenic hypertensive rats, TGR (mREN2)27, and its regulation by cAMP, angiotensin II, and calcium. J Clin Invest. 1993;91:742-747.
45. Sander M, Bader M, Djavidani B, Maser-Gluth C, Vecsei P, Mullins J, Ganten D, Peters J. The role of the adrenal gland in the hypertensive transgenic rats TGR(mREN2)27. Endocrinology. 1992;131:807-814.
46. Schnabel P, Böhm M, Gierschik P, Jakobs KH, Erdmann E. Improvement of cholera toxin-catalyzed ADP-ribosylation by endogenous ADP-ribosylation factor from bovine brain provides evidence for an unchanged amount of Gsα in failing human myocardium. J Mol Cell Cardiol. 1990;22:73-82.
47. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A, Hirt S, Döring V, Kalmar P, Höppner W, et al. Increased messenger RNA level of the inhibitory G-protein α-subunit Giα-2 in human end-stage heart failure. Circ Res. 1992;70:688-696.
48. Feldman AM, Cates AE, Bristow MR, van Dop C. Altered expression of alpha-subunits of G-proteins in failing human hearts. J Mol Cell Cardiol. 1989;21:359-365.
49. 2+. Mol Endocrinol. 1987;1:472-481.
50. Anand-Srivastava MB, Picard S, Thibault C. Altered expression of inhibitory guanine nucleotide regulatory proteins (Giα) in spontaneously hypertensive rats. Am J Hypertens. 1991;4:840-843.
51. Thibault C, Anand-Srivastava MB. Altered expression of G-protein mRNA in spontaneously hypertensive rats. FEBS Lett. 1992;313:160-164.
52. Mende U, Eschenhagen T, Geertz B, Schmitz W, Scholz H, Schulte am Esch J, Sempell R, Steinfath M. Isoprenaline-induced increase in the 40/41 kDa pertussis toxin substrates and functional consequences on contractile response in rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1992;345:44-50.
53. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Warnholtz A, Wüstel J-M. Isoprenaline-induced increase in mRNA levels of inhibitory G-protein α-subunits in rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1991;343:609-615.
54. Müller FU, Boheler KR, Eschenhagen T, Schmitz W, Scholz H. Isoprenaline stimulates gene transcription of the inhibitory G protein α-subunit Giα2 in rat heart. Circ Res. 1993;72:696-700.
55. Reithmann C, Werdan K. Noradrenaline-induced desensitization in cultured heart cells as a model for the defects of adenylate cyclase system in severe heart failure. Naunyn Schmiedebergs Arch Pharmacol. 1989;339:138-144.
56. Clark RB, Kunkel MW, Friedman J, Goka TJ, Johnson JA. Activation of cAMP-dependent protein kinase is required for heterologous desensitization of adenylyl cyclase in S49 wild-type lymphoma cells. Proc Natl Acad Sci USA. 1988;85:1442-1446.
57. Gende OA, Mattiazzi A, Camilion MC, Pedroni P, Taquini C, Llambi HG, Cingolani HE. Renal hypertension impairs inotropic isoproterenol effect without β-receptor changes. Am J Physiol. 1985;249:H814-H819.
58. Böhm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erdmann E. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation. J Cardiovasc Pharmacol. 1988;12:726-732.
59. Feldman MD, Copelas L, Gwathmey JK, Philips P, Warren SE, Schoen FJ, Grossman W, Morgan JP. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation. 1987;75:331-339.